Hims & Hers Health Slides as Traders Fade Peptide Rally

Hims & Hers Health, Inc. (HIMS) is down 10.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a sell-the-news reversal after a sharp rally tied to the FDA advisory committee’s favorable peptide votes. While that outcome supports Hims & Hers’ longer-term peptide ambitions, the committee action was only a recommendation rather than a final regulatory change, which may have led traders to lock in gains quickly.

Details:

The FDA’s Pharmacy Compounding Advisory Committee met on July 23-24, 2026 to review seven peptides for possible inclusion on the 503A bulks list, a process that could expand legal compounding pathways for some products.

During the meeting, outside advisers backed adding several closely watched peptides, including BPC-157, KPV, TB-500, and MOTS-c, creating an initially bullish read for companies exposed to peptide compounding.

Hims & Hers has already positioned itself for that theme through its earlier acquisition of a California peptide facility and has described peptide therapy as one of its emerging care categories.

The stock’s trading pattern points to reversal pressure: shares opened at $33.55, traded as high as $34.53 intraday, and then fell to close near $29.47, suggesting enthusiasm faded as investors reassessed the timing and certainty of any commercial benefit.

Sources:

FDA, Hims & Hers, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HIMS Insider Trading Activity

$HIMS insiders have traded $HIMS stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 133,499 shares for an estimated $3,781,155.
MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,316 shares for an estimated $2,843,915.
DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
MOHAMED ELSHENAWY (CTO) sold 30,040 shares for an estimated $946,260
PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $507,029.
SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HIMS Hedge Fund Activity

We have seen 229 institutional investors add shares of $HIMS stock to their portfolio, and 246 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 14,322,912 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $297,343,653
GOLDMAN SACHS GROUP INC removed 7,892,648 shares (-76.3%) from their portfolio in Q1 2026, for an estimated $163,851,372
DEFIANCE ETFS, LLC added 7,424,258 shares (+inf%) to their portfolio in Q1 2026, for an estimated $154,127,596
MORGAN STANLEY added 4,959,856 shares (+126.2%) to their portfolio in Q1 2026, for an estimated $102,966,610
FARALLON CAPITAL MANAGEMENT LLC removed 3,376,986 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $70,106,229
BANK OF AMERICA CORP /DE/ added 2,877,550 shares (+194.4%) to their portfolio in Q1 2026, for an estimated $59,737,938
RENAISSANCE TECHNOLOGIES LLC removed 2,699,929 shares (-56.0%) from their portfolio in Q1 2026, for an estimated $56,050,526

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HIMS Price Targets

Multiple analysts have issued price targets for $HIMS recently. We have seen 13 analysts offer price targets for $HIMS in the last 6 months, with a median target of $28.0.

Here are some recent targets:

Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.